Genomics Squatter
Executive Summary
Armed with a purification technology it uses to isolate human DNA from the much more abundant nonhuman DNA found in stool samples, Exact Sciences is taking already-known disease-associated genomics markers into the clinical diagnostics setting. With the May announcement of the availability of its first test, for a rare form of colorectal cancer, the company is gaining visibility and traction.
You may also be interested in...
Exact Sciences Buys Time with Genzyme Deal
On the heels of its rejection of a buyout from Sequenom, Exact Sciences announced a $24.5 million IP licensing deal with Genzyme. The transaction effectively halted Sequenom's takeover effort and bought Exact time for clinical development of a next-generation version of its stool-based colorectal cancer screening test. It'sa hefty deal, but Exact's path to sustainability remains problematic.
Exact Sciences' Moment
Exact Sciences and its distribution partner, LabCorp are on the verge of launching a new molecular test for colon cancer screening. They've taken deal-making in diagnostics to a new level, but now they have to deliver on their promises.
Exact Sciences' Moment
Exact Sciences and its distribution partner, LabCorp are on the verge of launching a new molecular test for colon cancer screening. They've taken deal-making in diagnostics to a new level, but now they have to deliver on their promises.